Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-01-18
2011-01-18
Rao, Deepak (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S243000, C544S315000, C544S318000
Reexamination Certificate
active
07872012
ABSTRACT:
Disclosed are pyrimidinone compounds having formula (I), a preparation and use thereof. The compounds are inhibitors of HMG-CoA reductase, and therefore have antivirus activities and are useful for preventing and treating cardiovascular and cerebrovascular disorders, senile dementia, diabetes mellitus, osteoporosis and tumors, and enhancing immune functions in a subject, and especially useful for treating diseases associated with hyperlipaemia.
REFERENCES:
patent: 5011930 (1991-04-01), Fujikawa et al.
patent: 5034399 (1991-07-01), Hubsch et al.
patent: 5260440 (1993-11-01), Hirai et al.
patent: 5300477 (1994-04-01), Tice
patent: 30 45 342 (1982-07-01), None
patent: WO 2004/014872 (2004-02-01), None
Simone, Oncology: Introduction, Cecil Textbook of Medicine, 20th Edition, vol. 1, pp. 1004-1010, 1996.
Bundgaard, Design of Prodrugs, p. 1, 1985.
Wolff, Some consideration for prodrug design, Burger's Medicinal Chemistry and Drug Discovery, 5th Edition, vol. I: Principles and Practice, pp. 975-977, 1995.
Banker et al., Prodrugs, Modern Pharmaceutics, Third Edition, Revised and Expanded, pp. 451 and 596.
Damasio, Alzheimer's Disease and Related Dementias, Cecil Textbook of Medicine, 20thEdition, vol. 2, pp. 1992-1996, 1996.
Layzer, Degenerative Diseases of the Nervous System, Cecil Textbook of Medicine, 20thEdition, vol. 2, pp. 2050-2057, 1996.
West, Solid Solutions, Solid State Chemistry and its applications, pp. 358 & 365, 1988.
Ulrich, Chapter 4: Crystal Characteristics, Kirk Othmer Encyclopedia of Chemical Technology (7 pages), Aug. 2002.
Vippagunta et al., Crystalline Solids, Advanced Drug Delivery Reviews, 48, pp. 3-26, 2001.
Danesh et al., Modulatory effects of HMG-CoA reductase inihbitors in diabetic microangiopathy, The FASEB Journal, vol. 18, pp. 805-815, May 2004.
Vega et al., PubMed Abstract (Circulation 84(1):118-28), 1991.
Supplementary European Search Report issued in corresponding European Patent Application No. 05824250.4, dated Sep. 9, 2008.
International Search Report for WO 2006/066512 dated Feb. 14, 2006.
Zheng, Hu,Pharmaceutical Chemistry, Ed. 4, People's Sanitation Publishing House, Beijing, China, (Dec. 2004) 194-195.
Knobbe Martens Olson & Bear LLP
Rao Deepak
Zhejiang Hisun Pharma Co., Ltd.
LandOfFree
Pyrimidinone compounds and preparation and use thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pyrimidinone compounds and preparation and use thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyrimidinone compounds and preparation and use thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2726703